NCT06763783 - Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases | Biotech Hunter

Enrollment

240

Participants

Timeline

Start Date

December 17, 2024

Primary Completion Date

December 31, 2029

Study Completion Date

June 30, 2034

Conditions

Systemic VasculitisSpondylarthropathiesPsoriatic ArthritisSclerodermaPolymyalgia Rheumatica (PMR)Juvenile Chronic ArthritisPolyarthritisSLEGiant Cell Arteritis (GCA)

Interventions

DRUG

Shingrix

all participants vaccinates with two doses of Shingrix vaccine

DRUG

vaccination with 2 doses of Shingrix vaccine

all participants will receive vaccination with 2 doses of Shingrix vaccine. The response to caccine will be compared bitween patients treated with immunosupressive drugs and these not receiving immunosuppresive treatment

Trial Locations (1)

SE-221 85

Skåne University Hospital, section for rheumatology, Lund